1rituximab target
CD20 cells
2rituximab drug type
naked MAB
4alemtuzumab drug type
naked MAB
6ceruzimab drug type
naked MAB
7trastuzumab target
HER2/neu protein
8trastuzumab drug type
naked MAB
10bevacizumab drug type
naked MAB
11advantage of MAB joined to chemotherapy
higher tumor selectivity while improving tolerability of the drug
12advantages of MABs bound to radiotherapy
MAB targets cancer cell, bringing radioactiv risootope to it. The radiation will also kill neighboring cells, which may include cancer cells that don't express the antigen. "Crossfire" effect.
13blinatumomab is used to treat
lymphocytic leukemia
14blinatumomab drug type
BiTE antibody
15B7 1 or 2 binding to t-cells CTLA-4 will
inactivate them
16blocking the binding of B7 to CTLA-4 will
cause B7 to bind to CD28, allowing the t cells to be active and kill tumor cells.
17B7 binding to t-cells CD28 will
allow the t cells to be active and kill tumor cells
18anti CTLA4 antibodies drug type
immune checkpoint inhibitors
19anti CTLA-4 antibodies MOA
bind to CTLA-4, preventing the binding of B7
20Blinatumomab drug type
BiTE Antibody
21Amivantamab-vmjw drug type
BiTE Antibody
22Tebentafusp-tebn drug type
BiTE Antibody
23Mosunetuzumab drug type
BiTE Antibody
24Teclistamab drug type
BiTE Antibody
25PD-L1 on tumor cells binding to PD-1 on T cells will
stop t cell activation
26blocking PD-L1 from binding to PD-1 on T cells with an anti PD-L1 or anti PD-1 drug will
allow the t cell to kill the tumor
27ipilimumab drug type
CTLA-4 inhibitor
28nivolumab drug type
PD1 and LAG-3 Inhibitor
29relatlimab drug type
PD1 and LAG-3 Inhibitor
30pembrolizumab drug type
PD1 inhibitor
31cemiplimab drug type
PD1 inhibitor
32avelumab drug type
PD-L1 inhibitor
33durvalumab drug type
PD-L1 inhibitor
34atezolizumab drug type
PD-L1 inhibitor
35drugs that end in leucel drug type
CAR-T
36drugs that start with a number drug type
Radio
37drugs that are two words and dont end with leucel drug type
antibody drug conjugate (chemo)